Does the media prefer CRDF or SLN?

In the previous week, Cardiff Oncology had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 8 mentions for Cardiff Oncology and 5 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.37 beat Cardiff Oncology's score of 1.02 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TENX or CRDF?

In the previous week, Cardiff Oncology had 6 more articles in the media than Tenax Therapeutics. MarketBeat recorded 8 mentions for Cardiff Oncology and 2 mentions for Tenax Therapeutics. Cardiff Oncology's average media sentiment score of 1.02 beat Tenax Therapeutics' score of 0.50 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DMAC or CRDF?

In the previous week, Cardiff Oncology had 6 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 8 mentions for Cardiff Oncology and 2 mentions for DiaMedica Therapeutics. Cardiff Oncology's average media sentiment score of 1.02 beat DiaMedica Therapeutics' score of 0.76 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cardiff Oncology (CRDF) Competitors

$1.26 +0.01 (+0.80%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 0.00 (-0.32%)

As of 07:55 PM Eastern

Compare

CRDF vs. ABEO, SLN, PALI, TENX, and DMAC

Should you buy Cardiff Oncology stock or one of its competitors? MarketBeat compares Cardiff Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiff Oncology include Abeona Therapeutics (ABEO), Silence Therapeutics (SLN), Palisade Bio (PALI), Tenax Therapeutics (TENX), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry.

How does Cardiff Oncology compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Abeona Therapeutics has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	55.03	$71.18M	$0.97	5.79
Cardiff Oncology	$590K	146.01	-$45.85M	-$0.67	N/A

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Abeona Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Abeona Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Abeona Therapeutics' return on equity of -53.98% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

In the previous week, Cardiff Oncology had 8 more articles in the media than Abeona Therapeutics. MarketBeat recorded 8 mentions for Cardiff Oncology and 0 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 1.90 beat Cardiff Oncology's score of 1.02 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Abeona Therapeutics	Very Positive
Cardiff Oncology	Positive

Abeona Therapeutics presently has a consensus price target of $19.00, indicating a potential upside of 238.08%. Cardiff Oncology has a consensus price target of $9.80, indicating a potential upside of 677.78%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Abeona Therapeutics beats Cardiff Oncology on 9 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to Silence Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

In the previous week, Cardiff Oncology had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 8 mentions for Cardiff Oncology and 5 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.37 beat Cardiff Oncology's score of 1.02 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiff Oncology has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	146.01	-$45.85M	-$0.67	N/A
Silence Therapeutics	$560K	772.71	-$88.61M	-$1.59	N/A

Cardiff Oncology currently has a consensus target price of $9.80, indicating a potential upside of 677.78%. Silence Therapeutics has a consensus target price of $55.00, indicating a potential upside of 500.44%. Given Cardiff Oncology's higher probable upside, equities research analysts plainly believe Cardiff Oncology is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Cardiff Oncology has a net margin of -8,527.43% compared to Silence Therapeutics' net margin of -8,943.86%. Cardiff Oncology's return on equity of -95.51% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cardiff Oncology has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

Summary

Cardiff Oncology and Silence Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Palisade Bio currently has a consensus price target of $10.20, suggesting a potential upside of 431.25%. Cardiff Oncology has a consensus price target of $9.80, suggesting a potential upside of 677.78%. Given Cardiff Oncology's higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Palisade Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

In the previous week, Cardiff Oncology had 8 more articles in the media than Palisade Bio. MarketBeat recorded 8 mentions for Cardiff Oncology and 0 mentions for Palisade Bio. Cardiff Oncology's average media sentiment score of 1.02 beat Palisade Bio's score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Palisade Bio	Neutral
Cardiff Oncology	Positive

Palisade Bio has higher earnings, but lower revenue than Cardiff Oncology. Palisade Bio is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,333.09	-$16.78M	-$1.01	N/A
Cardiff Oncology	$590K	146.01	-$45.85M	-$0.67	N/A

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Palisade Bio has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Palisade Bio's return on equity of -36.79% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Summary

Palisade Bio beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Tenax Therapeutics currently has a consensus price target of $38.00, suggesting a potential upside of 193.89%. Cardiff Oncology has a consensus price target of $9.80, suggesting a potential upside of 677.78%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Cardiff Oncology had 6 more articles in the media than Tenax Therapeutics. MarketBeat recorded 8 mentions for Cardiff Oncology and 2 mentions for Tenax Therapeutics. Cardiff Oncology's average media sentiment score of 1.02 beat Tenax Therapeutics' score of 0.50 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenax Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Cardiff Oncology has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
Cardiff Oncology	$590K	146.01	-$45.85M	-$0.67	N/A

Tenax Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Tenax Therapeutics' return on equity of -56.32% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 3.1% of Tenax Therapeutics shares are held by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cardiff Oncology beats Tenax Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 8.5% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

DiaMedica Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. DiaMedica Therapeutics' return on equity of -77.15% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

DiaMedica Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

In the previous week, Cardiff Oncology had 6 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 8 mentions for Cardiff Oncology and 2 mentions for DiaMedica Therapeutics. Cardiff Oncology's average media sentiment score of 1.02 beat DiaMedica Therapeutics' score of 0.76 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DiaMedica Therapeutics has higher earnings, but lower revenue than Cardiff Oncology. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Cardiff Oncology	$590K	146.01	-$45.85M	-$0.67	N/A

DiaMedica Therapeutics currently has a consensus target price of $12.33, suggesting a potential upside of 94.16%. Cardiff Oncology has a consensus target price of $9.80, suggesting a potential upside of 677.78%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Cardiff Oncology beats DiaMedica Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDF vs. The Competition

Export

Metric	Cardiff Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$85.46M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	N/A	20.68	25.17	23.98
Price / Sales	146.01	336.69	553.76	120.62
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.88	8.26	10.76	6.41
Net Income	-$45.85M	$23.91M	$3.56B	$337.14M
7 Day Performance	6.78%	3.05%	1.37%	-0.48%
1 Month Performance	-29.21%	2.40%	0.81%	0.49%
1 Year Performance	-60.63%	56.35%	30.53%	28.16%

Cardiff Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDF Cardiff Oncology	3.266 of 5 stars	$1.26 +0.8%	$9.80 +677.8%	-60.1%	$85.46M	$590K	N/A	20	News Coverage Analyst Revision
ABEO Abeona Therapeutics	3.4431 of 5 stars	$5.75 -0.3%	$19.00 +230.4%	-1.5%	$328.86M	$14.54M	5.93	90
SLN Silence Therapeutics	3.2185 of 5 stars	$7.53 +8.7%	$55.00 +630.4%	+26.0%	$327.34M	$560K	N/A	100	News Coverage Positive News Analyst Forecast Gap Up
PALI Palisade Bio	1.4075 of 5 stars	$1.84 -1.6%	$10.20 +454.3%	+176.6%	$324.59M	$250K	N/A	10
TENX Tenax Therapeutics	3.1477 of 5 stars	$12.25 +2.1%	$38.00 +210.2%	+142.7%	$318.30M	N/A	N/A	9	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDF) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiff Oncology (CRDF) Competitors

CRDF vs. ABEO, SLN, PALI, TENX, and DMAC

How does Cardiff Oncology compare to Abeona Therapeutics?

Summary

How does Cardiff Oncology compare to Silence Therapeutics?

Summary

How does Cardiff Oncology compare to Palisade Bio?

Summary

How does Cardiff Oncology compare to Tenax Therapeutics?

Summary

How does Cardiff Oncology compare to DiaMedica Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiff Oncology (CRDF) Competitors

CRDF vs. ABEO, SLN, PALI, TENX, and DMAC

How does Cardiff Oncology compare to Abeona Therapeutics?

Which has better valuation & earnings, ABEO or CRDF?

Do insiders and institutionals believe in ABEO or CRDF?

Which has more risk and volatility, ABEO or CRDF?

Is ABEO or CRDF more profitable?

Does the media refer more to ABEO or CRDF?

Do analysts rate ABEO or CRDF?

Summary

How does Cardiff Oncology compare to Silence Therapeutics?

Does the media prefer CRDF or SLN?

Which has stronger earnings and valuation, CRDF or SLN?

Do analysts rate CRDF or SLN?

Is CRDF or SLN more profitable?

Do insiders and institutionals have more ownership in CRDF or SLN?

Which has more risk and volatility, CRDF or SLN?

Summary

How does Cardiff Oncology compare to Palisade Bio?

Do analysts prefer PALI or CRDF?

Which has more volatility & risk, PALI or CRDF?

Does the media favor PALI or CRDF?

Which has preferable earnings & valuation, PALI or CRDF?

Do institutionals & insiders have more ownership in PALI or CRDF?

Is PALI or CRDF more profitable?

Summary

How does Cardiff Oncology compare to Tenax Therapeutics?

Do analysts rate TENX or CRDF?

Does the media refer more to TENX or CRDF?

Which has more volatility & risk, TENX or CRDF?

Which has preferable valuation & earnings, TENX or CRDF?

Is TENX or CRDF more profitable?

Do insiders & institutionals hold more shares of TENX or CRDF?

Summary

How does Cardiff Oncology compare to DiaMedica Therapeutics?

Do insiders & institutionals hold more shares of DMAC or CRDF?

Is DMAC or CRDF more profitable?

Which has more volatility and risk, DMAC or CRDF?

Does the media favor DMAC or CRDF?

Which has better valuation and earnings, DMAC or CRDF?

Do analysts prefer DMAC or CRDF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools